BNP PARIBAS ASSET MANAGEMENT Holding S.A. decreased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 8.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 438,211 shares of the specialty pharmaceutical company's stock after selling 39,353 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 0.69% of Jazz Pharmaceuticals worth $46,770,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Rise Advisors LLC raised its position in shares of Jazz Pharmaceuticals by 2,255.6% in the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company's stock valued at $26,000 after purchasing an additional 203 shares in the last quarter. Versant Capital Management Inc raised its holdings in Jazz Pharmaceuticals by 13,450.0% in the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock valued at $29,000 after acquiring an additional 269 shares in the last quarter. GAMMA Investing LLC boosted its stake in Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock valued at $31,000 after acquiring an additional 116 shares during the last quarter. Cape Investment Advisory Inc. grew its holdings in Jazz Pharmaceuticals by 14,600.0% during the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company's stock worth $36,000 after acquiring an additional 292 shares in the last quarter. Finally, Gladius Capital Management LP bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter worth about $33,000. Hedge funds and other institutional investors own 89.14% of the company's stock.
Analyst Ratings Changes
A number of equities analysts recently commented on the company. UBS Group decreased their price target on Jazz Pharmaceuticals from $117.00 to $113.00 and set a "neutral" rating for the company in a research note on Tuesday, July 2nd. Wells Fargo & Company decreased their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating for the company in a research report on Thursday, August 1st. The Goldman Sachs Group initiated coverage on Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They set a "buy" rating and a $169.00 price target on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an "overweight" rating in a report on Monday, August 19th. Finally, Royal Bank of Canada dropped their target price on shares of Jazz Pharmaceuticals from $175.00 to $174.00 and set an "outperform" rating on the stock in a report on Thursday, August 1st. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $173.07.
Get Our Latest Report on JAZZ
Jazz Pharmaceuticals Stock Performance
Shares of NASDAQ:JAZZ traded up $0.38 on Friday, hitting $115.98. The company's stock had a trading volume of 365,743 shares, compared to its average volume of 661,447. The company has a market capitalization of $7.31 billion, a price-to-earnings ratio of 23.91, a price-to-earnings-growth ratio of 1.76 and a beta of 0.58. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.90 and a current ratio of 2.37. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $146.70. The stock's 50-day moving average is $109.54 and its two-hundred day moving average is $112.79.
About Jazz Pharmaceuticals
(
Free Report)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Featured Stories
Before you consider Jazz Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.
While Jazz Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
